Cancer treatments have changed dramatically over the past decade, but have our dose-finding strategies kept pace?

In this episode, I speak with Dr. Ayon Mukherjee, who leads statistical innovation in early oncology development at Eli Lilly. Together, we explore Project Optimus, the FDA initiative that is changing how we think about dose optimization in oncology.

Instead of simply finding the highest dose patients can tolerate, Project Optimus encourages us to identify the dose that provides the best balance between efficacy, safety, pharmacokinetics, pharmacodynamics, and long-term tolerability.

Ayon explains why the traditional maximum tolerated dose approach worked well for chemotherapy but often falls short for targeted therapies and immunotherapies. We also discuss how statisticians can help lead this transformation by designing better dose optimization studies and collaborating more effectively with clinicians, pharmacologists, and regulators.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry. Innehållet i podden är skapat av Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry och inte av, eller tillsammans med, Poddtoppen.